Evommune (EVMN) Accumulated Expenses (2024 - 2026)

Evommune (EVMN) has 3 years of Accumulated Expenses data on file, last reported at $1.3 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $1.3 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.3 million (changed N/A YoY), and the FY2025 annual result was $9.5 million, up 41.88% from the prior year.
• Accumulated Expenses retreated to $1.3 million in Q1 2026 per EVMN's latest filing, from $9.5 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $9.5 million in Q4 2025 and troughed at $1.3 million in Q1 2026.
• A 3-year average of $6.0 million and a median of $6.5 million in 2024 frame the typical range for Accumulated Expenses.
• On a YoY basis, Accumulated Expenses climbed as much as 41.88% in 2025 and fell as far as 41.88% in 2025.
• A 3-year view of Accumulated Expenses shows it stood at $6.7 million in 2024, then surged by 41.88% to $9.5 million in 2025, then plunged by 86.44% to $1.3 million in 2026.
• Business Quant data shows EVMN's Accumulated Expenses at $1.3 million in Q1 2026, $9.5 million in Q4 2025, and $6.3 million in Q3 2025.